Generic drug
Sirolimus price, strengths & recalls
Pharmacies pay $21.38 for 30 tablets of Sirolimus 1 mg tablet this week, and from $21.38 to $252.57 across its 4 priced strengths and forms. 17 manufacturers make it. 1 recall is ongoing. Its official label last changed on January 29, 2026.
1 open recallGeneric- Fair cash price
- $35.09
- Strengths
- 4
- Makers
- 17
- Updated
- Nov 11
Sirolimus price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 1 mg/mL oral solution | $4.21 | $252.57 / 60 mL |
| 0.5 mg tablet | $0.8326 | $24.98 / 30 tablets |
| 1 mg tablet | $0.7127 | $21.38 / 30 tablets |
| 2 mg tablet | $2.35 | $70.65 / 30 tablets |
The lowest cost per tablet is 1 mg tablet at $0.7127. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Sirolimus
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SIROLIMUS TABLETS safely and effectively. See full prescribing information for SIROLIMUS TABLETS.SIROLIMUS tablets, for oral useInitial U.S. Approval: 1999
WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
•
Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression
Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.1)].
•
The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended [see Warnings and Precautions (5.2, 5.3)].
•
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT)
The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss in a study in de novo liver transplant patients. Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation and most led to graft loss or death [see Warnings and Precautions (5.2)].
•
Lung Transplantation - Bronchial Anastomotic Dehiscence
Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen [see Warnings and Precautions (5.3)].
WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
See full prescribing information for complete boxed warning.
•
Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression (5.1). Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants.
•
The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended (5.2, 5.3).
•
Liver Transplantation - Excess mortality, graft loss, and hepatic artery thrombosis (5.2).
•
Lung Transplantation - Bronchial anastomotic dehiscence (5.3).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021110 · Pf Prism Cv
- First approved
- August 25, 2000 (26 years ago)
- Latest approved change
- August 22, 2022
- Approved label
- PDF, Aug 23, 2022
- Generic makers
- 10 approved generic applications on the market
Sirolimus questions
How much does sirolimus cost without insurance?
Pharmacies pay about $21.38 for 30 tablets of sirolimus 1 mg tablet ($0.7127 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $35.09. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is sirolimus in shortage?
No shortage is reported for sirolimus right now. We check the national shortage list every day.
Has sirolimus been recalled?
6 recalls on record, 1 ongoing. Recalls name specific lots - check yours.
When did the sirolimus label last change?
The official label was last updated on January 29, 2026 (version 4). See what changed.
Talk about sirolimus
No comments yet. Questions, tips, what worked for you - start the conversation.